The deal size was increased to $125M in common stock from $100M in common stock. Goldman Sachs, BofA, Barclays and Oppenheimer acted as joint book running managers for the offering.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals announces $100M common stock offering
- Tarsus Pharmaceuticals price target raised to $58 from $54 at Jefferies
- Tarsus Pharmaceuticals’ Earnings Call Highlights Success and Challenges
- Hold Rating for Tarsus Pharmaceuticals Amid Strong Sales and Market Uncertainties
- Guggenheim ups Tarsus Pharmaceuticals price target, would buy on weakness